Keyphrases
Cardiovascular Effects
100%
Exenatide
100%
Immediate Release
100%
Glucagon-like
100%
Cardiovascular Disease Events
80%
Liraglutide
80%
Antidiabetic Drugs
60%
Exenatide Extended-release
60%
Cardiovascular Disease
40%
Type 2 Diabetes Mellitus (T2DM)
40%
Event Rate
40%
Hazard Ratio
40%
Peripheral Arterial Disease
20%
Ischemic Heart Disease
20%
Patient Characteristics
20%
Cardiovascular Risk
20%
Congestive Heart Failure
20%
Major Adverse Cardiovascular Events
20%
Prescribers
20%
Metformin
20%
Non-associated
20%
Cox Proportional Hazards Regression
20%
Prescription Refill
20%
Ischemic Events
20%
Administrative Claims Data
20%
Extended Release
20%
Active Comparator
20%
Time-varying Exposure
20%
Disease Component
20%
Plan Characteristics
20%
Refill Adherence
20%
Medicine and Dentistry
Exenatide
100%
Cardiovascular Effect
100%
Glucagon-Like Peptide-1 Agonist
100%
Cardiovascular Disease
87%
Liraglutide
50%
Glucagon Like Peptide 1
37%
Maturity Onset Diabetes of the Young
25%
Hazard Ratio
25%
Arteriosclerosis Obliterans
12%
Cohort Analysis
12%
Proportional Hazards Model
12%
Apoplexy
12%
Glycon
12%
Congestive Heart Failure
12%
Ischemic Heart Disease
12%
Pharmacology, Toxicology and Pharmaceutical Science
Glucagon Like Peptide 1 Receptor Agonist
100%
Exendin 4
100%
Cardiovascular Disease
87%
Liraglutide
50%
Glucagon-Like Peptide-1
37%
Non Insulin Dependent Diabetes Mellitus
25%
Cohort Study
12%
Peripheral Occlusive Artery Disease
12%
Congestive Heart Failure
12%
Metformin
12%
Cerebrovascular Accident
12%
Ischemic Heart Disease
12%